News of Note—Seqirus, VBI and Altimmune

Newspapers
Approval of Fluad in the U.K. is among this week's news of note.

> The U.K.’s Medicines and Healthcare products Regulatory Agency has cleared Seqirus’ adjuvanted trivalent influenza vaccine Fluad for use in people aged 65 years or older, 20 years after it was made available in other European countries. PharmaTimes article

> The FDA has accepted VBI Vaccines’ investigational new drug application for VBI-1901, an immunotherapy targeting glioblastoma multiforme. Release

> Altimmune submitted an IND application for its intranasally administered recombinant flu vaccine candidate NasoVAX. Release

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.